Organogenesis
Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes advanced wound care and surgical biologic products for hospitals, outpatient wound centers, and physician offices. Its portfolio includes cellular and acellular tissue-based products used to treat chronic and acute wounds, as well as products for surgical and sports medicine applications. The company generates revenue by selling these FDA-regulated biologic and medical device products through direct sales and distributor channels primarily in the United States and select international markets.
- Revenue
- $250M - $1B
- Employees
- 201 - 1,000
- Founded
- 1985
- Headquarters
- Canton, United States of America
Organogenesis customers on Arbolus
Customers who reviewed Organogenesis
Seniority of Organogenesis customers
Most people who reviewed Organogenesis hold C-Suite roles (77%), followed by Manager (15%) and Director (8%).
- C-Suite 77%
- Manager 15%
- Director 8%
Customers sample
Employer names and spend open in the full report, along with the other 11 customers.
What 14 Arbolus experts think of Organogenesis
Overall sentiment: Positive
NPS scores range from 3 to 10, with most responses at 7 or above, indicating generally positive feedback. Renewal intent is predominantly affirmative among high spenders and influencers, with a minority of users expressing uncertainty. 80% of experts have more than one year of adoption, reflecting strong stickiness. Key themes include positive clinical impact in complex cases, product selectivity based on evidence, and sensitivity to cost and budgetary constraints.
Everything 14 customers told us about Organogenesis.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
0 Net Promoter Score, from 14 scored reviews- Promoters 2
- Passives 10
- Detractors 2
Praised
- Specialized Options for Difficult Cases
- Effective in Complex and Chronic Wounds
- Clinical Evidence-backed Solutions
- Selective Expansion Through Data
Criticised
- Competitive Value Offers
- High Cost Sensitivity
- AI as a Complement or Threat
- Comparative Evidence Gaps
What Organogenesis customers say
Specialized Options for Difficult Cases
“I find their specialized range provides additional treatment options for wounds that haven't responded to standard care, reducing the need for repeat interventions.”
Effective in Complex and Chronic Wounds
“I use Organogenesis mainly for wounds slow to heal with standard treatments, especially diabetic foot ulcers, and have seen benefits in promoting wound closure.”
Clinical Evidence-backed Solutions
“I prioritize Organogenesis products when there’s strong clinical support and evidence that the product fits established wound care pathways.”
Renewal intent
Plan to renew 40%Plan to renew, by seniority
- 50% 2 answers
- 100% 1 answer
- 0% 2 answers
- 9/10 Average score from customers who will renew
- 5.3/10 Average score from undecided customers
Report
For people who use Organogenesis
Do you use Organogenesis at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 14 customers of Organogenesis have already contributed
Takes a few minutes. Your identity stays anonymous.